The future of long-acting agents for preexposure prophylaxis
C Flexner - Current Opinion in HIV and AIDS, 2022 - journals.lww.com
C Flexner
Current Opinion in HIV and AIDS, 2022•journals.lww.comLong-acting antiretroviral products have substantial promise for PrEP and have particular
advantages over daily oral drugs based mainly on improved adherence. However, there are
barriers to further uptake that include the need for more intensive interaction with systems of
healthcare delivery, greater expense and complexity of implementation, and unexpected
long-term toxicities.
advantages over daily oral drugs based mainly on improved adherence. However, there are
barriers to further uptake that include the need for more intensive interaction with systems of
healthcare delivery, greater expense and complexity of implementation, and unexpected
long-term toxicities.
Summary
Long-acting antiretroviral products have substantial promise for PrEP and have particular advantages over daily oral drugs based mainly on improved adherence. However, there are barriers to further uptake that include the need for more intensive interaction with systems of healthcare delivery, greater expense and complexity of implementation, and unexpected long-term toxicities.
Lippincott Williams & Wilkins